论文部分内容阅读
目的:探讨丹红注射液联合多巴酚丁胺治疗慢性肺源性心脏病(简称肺心病)心力衰竭(HF)的临床疗效。方法:将86例肺心病HF患者随机分为治疗组(n=46)和对照组(n=40),两组病例在年龄、性别、吸烟史、临床症状、体征、美国纽约心脏协会(NYHA)心功能分级、血气分析、血常规及血液流变学等方面差异无统计学意义(p>0.05)。两组均采用吸氧、抗炎、强心利尿、扩血管、纠正酸碱平衡及水电解质紊乱等常规治疗,治疗组同时加用丹红注射液30ml加入5%葡萄糖注射液250ml静滴,每日1次,多巴酚丁胺40mg加入5%葡萄糖液250ml内静滴,滴速15滴/min,每日1次,14天为一疗程。结果:治疗组与对照组相比,治疗后心率、呼吸频率、动脉血二氧化碳分压、高切黏度、低切黏度、还原黏度、血浆黏度、纤维蛋白原明显下降,动脉血氧饱和度、动脉血氧分压、射血分数明显上升,NYHA心功能分级好转,差异均具有统计学意义(p<0.05)。治疗组总有效率91.3%(42/46)与对照组75.0%(30/40)相比差异有统计学意义(p<0.05)。结论:丹红注射液联合多巴酚丁胺治疗肺心病HF具有安全可靠、见效快、疗程短、毒副作用小等诸多优点,值得临床推广应用。
Objective: To investigate the clinical efficacy of Danhong injection combined with dobutamine in the treatment of heart failure with chronic cor pulmonale (HF). Methods: Eighty-six patients with HF were randomly divided into treatment group (n = 46) and control group (n = 40). The age, sex, smoking history, clinical symptoms and signs of the two groups were compared. NYHA There was no significant difference in cardiac function classification, blood gas analysis, blood routine and hemorheology (p> 0.05). The two groups were treated with oxygen, anti-inflammatory, cardiac diuresis, vasodilation, correct acid-base balance and water and electrolyte disorders and other conventional treatment, the treatment group also added Danhong injection 30ml 5% glucose injection 250ml intravenous infusion, Day 1, dobutamine 40mg added 5% glucose solution 250ml intravenous drip, drip rate 15 drops / min, day 1, 14 days for a course of treatment. Results: Compared with the control group, the heart rate, respiratory rate, arterial carbon dioxide partial pressure, high shear viscosity, low shear viscosity, reducing viscosity, plasma viscosity, fibrinogen, arterial oxygen saturation, Blood oxygen partial pressure, ejection fraction increased significantly, NYHA cardiac function improved, the differences were statistically significant (p <0.05). The total effective rate was 91.3% (42/46) in the treatment group and 75.0% (30/40) in the control group, the difference was statistically significant (p <0.05). Conclusion: Danhong injection combined with dobutamine for the treatment of pulmonary heart disease has many advantages, such as safe, reliable, quick response, short course of treatment and small toxic and side effects. It is worthy of clinical application.